Tonix Pharmaceuticals Holding (TNXP) Revenue (2022 - 2026)

Tonix Pharmaceuticals Holding's Revenue history runs 5 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Revenue rose 183.16% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $17.6 million, a 74.84% increase from a year earlier, with the FY2025 full-year figure at $13.1 million, up 29.85% from the prior year.
• Revenue improved to $6.9 million in Q1 2026 per TNXP's latest filing, from $5.4 million in the prior quarter.
• Across five years, Revenue topped out at $6.9 million in Q1 2026 and bottomed at $2.0 million in Q2 2025.
• The 5-year median for Revenue is $3.4 million (2023), against an average of $3.6 million.
• Across the five-year window, Revenue sank 37.7% in 2024 and soared 183.16% in 2026, its largest moves.
• Year by year, Revenue stood at $3.6 million in 2022, then increased by 3.96% to $3.8 million in 2023, then sank by 31.68% to $2.6 million in 2024, then soared by 108.75% to $5.4 million in 2025, then gained by 27.61% to $6.9 million in 2026.
• Per Business Quant, the three latest TNXP Revenue figures stand at $6.9 million (Q1 2026), $5.4 million (Q4 2025), and $3.3 million (Q3 2025).